Skip to main content
TipRanks
Go Ultimate75% OFF

Fresenius SE & Co (FSNUY) AI Stock Analysis

94 Followers
FSNUY

Fresenius SE & Co

(Other OTC:FSNUY)

Select Model
Rating:78Outperform
Price Target:$16.50▲(11.58% Upside)
Action:reiterated
Date:11/07/26

The score is supported primarily by improved profitability and a substantially healthier balance sheet, reinforced by positive earnings guidance and operating momentum. Inconsistent cash-flow quality and strongly overbought technical indicators, together with only moderate valuation appeal, limit the overall score.

Positive Factors
Broad-based growth and margin expansionBroad-based revenue growth and double-digit EBIT expansion indicate improving operating performance across the portfolio rather than reliance on a single business. Higher margins and raised full-year targets strengthen earnings durability and support reinvestment over the next several quarters.
Negative Factors
Tyenne supply and formulary pressureFormulary deterioration can reduce access to patients and weaken product economics, while supply constraints prevent Fresenius from fully converting strong demand into revenue. Together, these issues may limit near-term biopharma growth and delay operating leverage.

Fresenius SE & Co (FSNUY) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%FSNUY+9.70%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$133.46B
Dividend Yield
2.03%
Average Volume (3M)
93.62K
Price to Earnings (P/E)
19.2
Beta (1Y)
0.32
Revenue Growth
12.01%
EPS Growth
41.39%
Country
US
Employees
178,394
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

Fresenius SE & Co Business Overview & Revenue Model

Company Description

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius...

Fresenius SE & Co Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:8.25%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call was strongly positive, with broad-based organic growth, double-digit earnings growth, higher margins, improved cash generation, stronger returns, maintained leverage and raised full-year guidance. Fresenius also reported significant progress in biopharma, MedTech, Nutrition, hospital operations and digital health. The main challenges were Tyenne supply constraints and formulary changes, Nutrition-related supply issues in China, Pharma pricing and volume pressure, Melrose Park remediation, higher planned R&D investment and weaker Q4 phasing at Helios. These issues were explicitly discussed but did not outweigh the operational improvements and upgraded outlook.

Positive Updates

Improved Full-Year Core EPS Guidance
Fresenius raised its full-year core EPS growth outlook and now expects growth in the upper half of the 10% to 15% range at constant currency.

Negative Updates

Tyenne Formulary Downgrade and Supply Constraints
Following UNH Optum formulary changes, Tyenne moved from preferred to nonpreferred status. Fresenius said U.S. demand continues to exceed current supply and that the company remains constrained despite securing additional supply and expanding capacity. U.S. market volumes increased 45% year-over-year.

Company Guidance

Fresenius now expects full-year core EPS growth in the upper half of its 10% to 15% guidance range at constant currency, group EBIT margin above 11.5%, full-year interest expense below EUR 300 million, and a tax rate between 24% to 25%; if exchange rates remain at the spot rate of 30th September, it expects no material impact on reported revenue, EBIT or net income for the full year. Kabi’s full-year EBIT margin indication remains 16.5% to 17%, its structural growth band remains applicable, and Nutrition is expected to have an improved growth trajectory for the fourth quarter; Helios overall as a segment is expected to deliver EBIT growth in 2027. The 2030 ambition to double biopharma revenue at an EBIT margin of around 20% remains unchanged, while the self-imposed leverage corridor of 2.5 to 3x remains unchanged.

Fresenius SE & Co Financial Statement Overview

Summary

Profitability and the balance sheet improved materially, with TTM net income of $1.6 billion, debt reduced to $11.8 billion, and equity increased to $20.5 billion. Cash-flow quality remains the main weakness because free cash flow covered only about 51.5% of net income and has been inconsistent.

Income Statement

78Positive

Balance Sheet

82Very Positive

Cash Flow

62Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue23.94B21.97B21.83B22.30B40.84B37.52B
Gross Profit6.18B5.47B5.38B5.06B10.72B10.31B
EBITDA3.50B3.17B3.14B2.73B3.10B6.86B
Net Income1.56B1.21B471.00M-594.00M1.37B1.82B
Balance Sheet
Total Assets42.24B41.38B43.55B45.28B76.42B71.96B
Cash, Cash Equivalents and Short-Term Investments1.85B1.58B2.05B2.56B2.35B2.75B
Total Debt11.84B11.93B13.58B15.83B27.76B27.16B
Total Liabilities21.49B21.62B23.26B25.63B44.20B42.67B
Stockholders Equity20.51B19.10B19.54B19.00B20.41B19.00B
Cash Flow
Free Cash Flow1.29B1.15B1.52B3.32B2.28B3.03B
Operating Cash Flow2.82B2.59B2.45B4.46B4.20B5.08B
Investing Cash Flow-322.28M-904.82M-510.00M-3.19B-2.61B-2.82B
Financing Cash Flow-3.16B-2.32B-2.18B-1.38B-1.60B-1.45B

Fresenius SE & Co Technical Analysis

Technical Analysis SentimentPositive
Last Price14.79

Price Trends

50DMA13.16Positive
100DMA12.97Positive
200DMA12.81Positive

Market Momentum

MACD0.57Negative
RSI74.43Negative
STOCH77.89Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Positive. The current price of 14.79 is above the 20-day moving average (MA) of 13.89, above the 50-day MA of 13.16, and above the 200-day MA of 12.81, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 74.43 is Negative, neither overbought nor oversold. The STOCH value of 77.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSNUY.

Fresenius SE & Co Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

FSNUY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
THCTHC87Outperform$23.20B8.4160.60%―6.23%136.09%
FSNUYFSNUY78Outperform$33.01B19.237.83%2.03%12.01%41.39%
OPCHOPCH72Outperform$4.75B22.7816.36%―4.01%9.94%
FMSFMS66Neutral$11.64B13.336.34%3.95%4.27%26.14%
HCAHCA64Neutral$106.91B16.83-100.45%0.60%5.82%16.59%
DVADVA62Neutral$10.96B13.36-133.21%―6.38%36.05%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%50%100%FSNUYOPCHDVAFMSHCATHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FSNUY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FSNUYFresenius Se14.791.319.71%
OPCHOption Care Health Inc31.633.8613.90%
DVADaVita Inc.173.0057.8050.17%
FMSFresenius Medical Care21.69-0.48-2.17%
HCAHca Healthcare501.1923.404.90%
THCTenet Healthcare Corp.282.0787.8245.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026